Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial

D. E. Furst, P. J. Clements, W. K. Wong, M. D. Mayes, Fredrick Wigley, B. White, M. Weisman, W. Barr, L. Moreland, R. Martin, T. A. Medsger, V. Steen, D. Collier, A. Weinstein, E. Lally, J. Varga, S. R. Weiner, B. Andrews, M. Abeles, J. B. PeterJ. R. Seibold

Research output: Contribution to journalArticle

Abstract

Objectives. To compare the systemic sclerosis (SSc) patients entered into the D-penicillamine trial with SSc patients entered into previous controlled SSc trials. It was hypothesized that the D-penicillamine trial patients, who conformed to the American College of Rheumatology (ACR) guidelines for clinical trials in SSc were different from patients entered into previous trials. Methods. Patients entering a double-blind, randomized trial of low- vs high-dose D-penicillamine were described carefully and completely. Their characteristics were then compared with previously published data on SSc and its treatment. Results. One hundred and thirty-four patients had early [mean duration 9.5 (S.D. 4.2) months], diffuse [skin score 21 (8)] disease. Organ involvement in the patients was as follows: pulmonary 54%, cardiac 20%, joints 38%, muscular 20%. Thirty-three per cent had mild proteinuria and 13% were hypertensive when first seen. Compared with patients in most previous studies, these SSc patients had earlier disease and uniformly had diffuse disease. They had less muscular involvement, less dyspnoea, less abnormal pulmonary function and less cardiac and less renal involvement than patients in earlier studies. Conclusions. The use of the new ACR guidelines for SSc trials may change the nature of patient populations entering future studies.

Original languageEnglish (US)
Pages (from-to)615-622
Number of pages8
JournalRheumatology
Volume40
Issue number6
StatePublished - 2001

Fingerprint

Systemic Scleroderma
Clinical Trials
Guidelines
Penicillamine
Lung
Rheumatology
Proteinuria
Dyspnea
Joints
Kidney

Keywords

  • ACR guidelines for systemic sclerosis trials
  • Organ involvement
  • Scleroderma
  • Systemic sclerosis

ASJC Scopus subject areas

  • Neuroscience(all)
  • Rheumatology

Cite this

Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial. / Furst, D. E.; Clements, P. J.; Wong, W. K.; Mayes, M. D.; Wigley, Fredrick; White, B.; Weisman, M.; Barr, W.; Moreland, L.; Martin, R.; Medsger, T. A.; Steen, V.; Collier, D.; Weinstein, A.; Lally, E.; Varga, J.; Weiner, S. R.; Andrews, B.; Abeles, M.; Peter, J. B.; Seibold, J. R.

In: Rheumatology, Vol. 40, No. 6, 2001, p. 615-622.

Research output: Contribution to journalArticle

Furst, DE, Clements, PJ, Wong, WK, Mayes, MD, Wigley, F, White, B, Weisman, M, Barr, W, Moreland, L, Martin, R, Medsger, TA, Steen, V, Collier, D, Weinstein, A, Lally, E, Varga, J, Weiner, SR, Andrews, B, Abeles, M, Peter, JB & Seibold, JR 2001, 'Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial', Rheumatology, vol. 40, no. 6, pp. 615-622.
Furst, D. E. ; Clements, P. J. ; Wong, W. K. ; Mayes, M. D. ; Wigley, Fredrick ; White, B. ; Weisman, M. ; Barr, W. ; Moreland, L. ; Martin, R. ; Medsger, T. A. ; Steen, V. ; Collier, D. ; Weinstein, A. ; Lally, E. ; Varga, J. ; Weiner, S. R. ; Andrews, B. ; Abeles, M. ; Peter, J. B. ; Seibold, J. R. / Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial. In: Rheumatology. 2001 ; Vol. 40, No. 6. pp. 615-622.
@article{7afbc9f85c924a84a38c043bb2a42c80,
title = "Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial",
abstract = "Objectives. To compare the systemic sclerosis (SSc) patients entered into the D-penicillamine trial with SSc patients entered into previous controlled SSc trials. It was hypothesized that the D-penicillamine trial patients, who conformed to the American College of Rheumatology (ACR) guidelines for clinical trials in SSc were different from patients entered into previous trials. Methods. Patients entering a double-blind, randomized trial of low- vs high-dose D-penicillamine were described carefully and completely. Their characteristics were then compared with previously published data on SSc and its treatment. Results. One hundred and thirty-four patients had early [mean duration 9.5 (S.D. 4.2) months], diffuse [skin score 21 (8)] disease. Organ involvement in the patients was as follows: pulmonary 54{\%}, cardiac 20{\%}, joints 38{\%}, muscular 20{\%}. Thirty-three per cent had mild proteinuria and 13{\%} were hypertensive when first seen. Compared with patients in most previous studies, these SSc patients had earlier disease and uniformly had diffuse disease. They had less muscular involvement, less dyspnoea, less abnormal pulmonary function and less cardiac and less renal involvement than patients in earlier studies. Conclusions. The use of the new ACR guidelines for SSc trials may change the nature of patient populations entering future studies.",
keywords = "ACR guidelines for systemic sclerosis trials, Organ involvement, Scleroderma, Systemic sclerosis",
author = "Furst, {D. E.} and Clements, {P. J.} and Wong, {W. K.} and Mayes, {M. D.} and Fredrick Wigley and B. White and M. Weisman and W. Barr and L. Moreland and R. Martin and Medsger, {T. A.} and V. Steen and D. Collier and A. Weinstein and E. Lally and J. Varga and Weiner, {S. R.} and B. Andrews and M. Abeles and Peter, {J. B.} and Seibold, {J. R.}",
year = "2001",
language = "English (US)",
volume = "40",
pages = "615--622",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial

AU - Furst, D. E.

AU - Clements, P. J.

AU - Wong, W. K.

AU - Mayes, M. D.

AU - Wigley, Fredrick

AU - White, B.

AU - Weisman, M.

AU - Barr, W.

AU - Moreland, L.

AU - Martin, R.

AU - Medsger, T. A.

AU - Steen, V.

AU - Collier, D.

AU - Weinstein, A.

AU - Lally, E.

AU - Varga, J.

AU - Weiner, S. R.

AU - Andrews, B.

AU - Abeles, M.

AU - Peter, J. B.

AU - Seibold, J. R.

PY - 2001

Y1 - 2001

N2 - Objectives. To compare the systemic sclerosis (SSc) patients entered into the D-penicillamine trial with SSc patients entered into previous controlled SSc trials. It was hypothesized that the D-penicillamine trial patients, who conformed to the American College of Rheumatology (ACR) guidelines for clinical trials in SSc were different from patients entered into previous trials. Methods. Patients entering a double-blind, randomized trial of low- vs high-dose D-penicillamine were described carefully and completely. Their characteristics were then compared with previously published data on SSc and its treatment. Results. One hundred and thirty-four patients had early [mean duration 9.5 (S.D. 4.2) months], diffuse [skin score 21 (8)] disease. Organ involvement in the patients was as follows: pulmonary 54%, cardiac 20%, joints 38%, muscular 20%. Thirty-three per cent had mild proteinuria and 13% were hypertensive when first seen. Compared with patients in most previous studies, these SSc patients had earlier disease and uniformly had diffuse disease. They had less muscular involvement, less dyspnoea, less abnormal pulmonary function and less cardiac and less renal involvement than patients in earlier studies. Conclusions. The use of the new ACR guidelines for SSc trials may change the nature of patient populations entering future studies.

AB - Objectives. To compare the systemic sclerosis (SSc) patients entered into the D-penicillamine trial with SSc patients entered into previous controlled SSc trials. It was hypothesized that the D-penicillamine trial patients, who conformed to the American College of Rheumatology (ACR) guidelines for clinical trials in SSc were different from patients entered into previous trials. Methods. Patients entering a double-blind, randomized trial of low- vs high-dose D-penicillamine were described carefully and completely. Their characteristics were then compared with previously published data on SSc and its treatment. Results. One hundred and thirty-four patients had early [mean duration 9.5 (S.D. 4.2) months], diffuse [skin score 21 (8)] disease. Organ involvement in the patients was as follows: pulmonary 54%, cardiac 20%, joints 38%, muscular 20%. Thirty-three per cent had mild proteinuria and 13% were hypertensive when first seen. Compared with patients in most previous studies, these SSc patients had earlier disease and uniformly had diffuse disease. They had less muscular involvement, less dyspnoea, less abnormal pulmonary function and less cardiac and less renal involvement than patients in earlier studies. Conclusions. The use of the new ACR guidelines for SSc trials may change the nature of patient populations entering future studies.

KW - ACR guidelines for systemic sclerosis trials

KW - Organ involvement

KW - Scleroderma

KW - Systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=0034935514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034935514&partnerID=8YFLogxK

M3 - Article

C2 - 11426017

AN - SCOPUS:0034935514

VL - 40

SP - 615

EP - 622

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 6

ER -